Galaxy Super Speciality Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Galaxy Super Speciality Pharmaceutical Export Portfolio Dataset — 7 Products, $240.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Galaxy Super Speciality — Pharmaceutical Exporter Profile (2026) | 7 Products, $240.3K Trade | TransData Nexus

Product Portfolio — Top 7 by Export Value

Galaxy Super Speciality exports 7 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Sofosbuvir	Antiviral & HIV Medications	$124.8K	38	0.3%	11
2	Velpatasvir	Antiviral & HIV Medications	$76.4K	16	0.3%	11
3	Olaparib	Advanced Oncology	$10.6K	4	1.2%	10
4	Axitinib	Advanced Oncology	$9.4K	18	10.1%	2
5	Cabozantinib	Advanced Oncology	$8.5K	10	6.7%	3
6	Ledipasvir	Antiviral & HIV Medications	$6.8K	7	0.6%	14
7	Ribavirin	Antivirals	$3.7K	4	0.6%	6

Galaxy Super Speciality exports 7 pharmaceutical products across 3 therapeutic categories with a total export value of $240.3K. The top category is Antiviral & HIV Medications (86.6% of portfolio), followed by Advanced Oncology (11.9%), indicating a concentrated portfolio with the top 5 products accounting for 95.6% of total export value.

Galaxy Super Speciality — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Galaxy Super Speciality, established in 2006, is a specialized pharmaceutical exporter headquartered in New Delhi, India. The company focuses on providing life-saving medicines, including treatments for various types of cancer, hepatitis C and B, HIV, and other critical health conditions. Their product range encompasses pharmaceutical injections, tablets, capsules, syrups, and critical care products. Galaxy Super Speciality operates as a private entity, with a small team dedicated to its operations. The company's official website is galaxysuperspeciality.com.

2Manufacturing Facilities

Specific details regarding Galaxy Super Speciality's manufacturing facilities, including their locations, capacities, and specializations, are not publicly disclosed. The company emphasizes its role as a specialized solution provider for life-saving medicines, suggesting that its manufacturing operations are aligned with this focus.

3Key Leadership

The company's leadership includes Jasminder Singh, who serves as the Chief Executive Officer (CEO). Other key executives are not publicly listed, and detailed information about the management team is limited.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Galaxy Super Speciality Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Galaxy Super Speciality's export activities are primarily focused on providing life-saving medicines to international markets. While specific regulatory filings and approvals in the United States, European Union, United Kingdom, Australia, and Japan are not publicly detailed, the company's emphasis on international markets indicates compliance with relevant regulatory standards. The company's product range includes treatments for various types of cancer, hepatitis C and B, HIV, and other critical health conditions, suggesting adherence to international quality and regulatory standards.

2Emerging Markets

Galaxy Super Speciality's export activities encompass a global reach, including regions such as Africa, Latin America, and Southeast Asia. The company's focus on life-saving medicines positions it to meet the healthcare needs in these emerging markets. While specific details about WHO prequalification or other certifications enabling access to these markets are not publicly disclosed, the company's product offerings suggest a commitment to meeting international standards.

3Geographic Strategy

Galaxy Super Speciality — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Galaxy Super Speciality's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's emphasis on providing life-saving medicines suggests adherence to international quality standards, but without detailed regulatory filings, a comprehensive assessment of its FDA status cannot be made.

2WHO & EU GMP

Information regarding Galaxy Super Speciality's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines (EDQM) status is not publicly disclosed. The company's focus on life-saving medicines indicates a commitment to quality, but without specific certifications, the extent of compliance with WHO and EU GMP standards cannot be determined.

3CDSCO & Indian Regulatory

Galaxy Super Speciality's compliance with the Central Drugs Standard Control Organisation (CDSCO) and other Indian regulatory bodies is not publicly detailed. The company's emphasis on life-saving medicines suggests adherence to relevant Indian regulations, but without specific information on manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs), a comprehensive assessment cannot be made.

Galaxy Super Speciality — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Galaxy Super Speciality operates in the competitive pharmaceutical export market, focusing on life-saving medicines such as cancer treatments, hepatitis C and B therapies, and HIV medications. While specific competitors are not publicly detailed, the company's emphasis on providing specialized solutions positions it within a competitive landscape of pharmaceutical exporters. The company's product portfolio, including treatments like Sofosbuvir, Velpatasvir, Olaparib, Axitinib, and Cabozantinib, indicates a focus on high-demand therapeutic areas, suggesting competition with other exporters in these segments.

2Key Differentiators

Galaxy Super Speciality's key differentiators include its specialization in life-saving medicines and a diverse product portfolio covering critical therapeutic areas such as cancer, hepatitis C and B, HIV, and nephrology. The company's focus on providing pharmaceutical injections, tablets, capsules, syrups, and critical care products from various companies indicates a comprehensive approach to meeting diverse healthcare needs. Additionally, the company's emphasis on international markets suggests a global outreach and commitment to addressing global health challenges.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Galaxy Super Speciality as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Galaxy Super Speciality's track record in supplying life-saving medicines is demonstrated by its export activities, including 97 shipments valued at $240,000 USD across seven products in three therapeutic categories. The company's portfolio concentration is high, with the top five products accounting for 95.6% of total exports. The company's focus on high-demand therapeutic areas such as antiviral and HIV medications, advanced oncology, and antivirals indicates a strategic approach to meeting critical healthcare needs. However, the lack of publicly available information on the company's manufacturing facilities, regulatory approvals, and certifications makes it challenging to fully assess its reliability and consistency as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA) by checking the FDA's official website or contacting the manufacturer directly.

Frequently Asked Questions — Galaxy Super Speciality

How many pharmaceutical products does Galaxy Super Speciality export from India?

Galaxy Super Speciality exports 7 pharmaceutical products across 3 therapeutic categories. The top exports are Sofosbuvir ($124.8K), Velpatasvir ($76.4K), Olaparib ($10.6K), Axitinib ($9.4K), Cabozantinib ($8.5K). Total export value is $240.3K.

What is Galaxy Super Speciality's total pharmaceutical export value?

Galaxy Super Speciality's total pharmaceutical export value is $240.3K, based on 97 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Galaxy Super Speciality cover?

Galaxy Super Speciality exports across 3 therapeutic categories. The largest are Antiviral & HIV Medications (86.6%, 3 products), Advanced Oncology (11.9%, 3 products), Antivirals (1.5%, 1 products).

Get Full Galaxy Super Speciality Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Galaxy Super Speciality

Galaxy Super Speciality — Export Portfolio & Destination Treemap

Who is Galaxy Super Speciality? — Company Overview & Market Position

What Does Galaxy Super Speciality Export? — Product Portfolio Analysis

Top Products by Export Value

Galaxy Super Speciality Therapeutic Categories — 3 Specializations